Bayer Dealt Blow In Nexavar Feud With Cipla

Law360, New York (August 20, 2009, 2:09 PM EDT) -- In a setback for Bayer HealthCare AG, an Indian court has thrown out the German pharmaceutical giant’s legal battle to stop Indian generics maker Cipla Ltd. from producing a copycat version of its cancer treatment Nexavar.

The Delhi High Court on Tuesday dismissed Bayer’s lawsuit, which challenged the Indian company’s application with the Drugs Controller General of India to produce and sell Nexavar in India even though the drug's patent is protected through 2020 in that country, according to Lawyers Collective, a legal nonprofit that was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.